Clinical Trials
Study of Ivonescimab vs. Pembrolizumab for First line Treatment of NSCLC
Disease Type: Lung
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville